A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Summary

Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.

Timeline

Start

2009-09

Primary completion

2013-01

Completion

2013-01

Outcome

Outcome not reported

Stopped: “The study was terminated on 26 February 2013. Risk-benefit assessment is no longer positive and does not support further development”

Drugs

Indications